S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Amplia Therapeutics Stock Price, News & Analysis (ASX:ATX)

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume80,000 shs
Average VolumeN/A
Market Capitalization$4.22 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits FAK. The company also manufactures and sells drugs. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in North Melbourne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8003 3650

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50,474.00
Book ValueA$0.21 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$4.22 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ATX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATX and its competitors with MarketBeat's FREE daily newsletter.


Amplia Therapeutics (ASX:ATX) Frequently Asked Questions

What is Amplia Therapeutics' stock symbol?

Amplia Therapeutics trades on the ASX under the ticker symbol "ATX."

Has Amplia Therapeutics been receiving favorable news coverage?

News coverage about ATX stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amplia Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Amplia Therapeutics.

Who are some of Amplia Therapeutics' key competitors?

Who are Amplia Therapeutics' key executives?

Amplia Therapeutics' management team includes the folowing people:
  • Dr. John Lambert, Chief Exec. Officer
  • Mr. Jeff Carter MAppFin, BFinAdmin, Chief Financial Officer (Age 61)
  • Mr. Andrew J. Cooke L.L.B., LLB, FAICS, MAICD, FGIA, FCIS, Company Sec. & Independent Non-Exec. Director (Age 59)
  • Mark Devlin, Chief Scientific Advisor
  • Dr. Frank Gelder, Founding Scientist

How big of a company is Amplia Therapeutics?

Amplia Therapeutics has a market capitalization of $0.00 and generates $50,474.00 in revenue each year. View Additional Information About Amplia Therapeutics.

What is Amplia Therapeutics' official website?

The official website for Amplia Therapeutics is http://www.ampliatx.com/.

How can I contact Amplia Therapeutics?

The company can be reached via phone at 61 2 8003 3650.


MarketBeat Community Rating for Amplia Therapeutics (ASX ATX)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  1 (Vote Underperform)
Total Votes:  4
MarketBeat's community ratings are surveys of what our community members think about Amplia Therapeutics and other stocks. Vote "Outperform" if you believe ATX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel